These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 22645227)

  • 1. Neuroendocrine tumor disease: an evolving landscape.
    Frilling A; Akerström G; Falconi M; Pavel M; Ramos J; Kidd M; Modlin IM
    Endocr Relat Cancer; 2012 Oct; 19(5):R163-85. PubMed ID: 22645227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
    Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
    Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors.
    Lawrence B; Gustafsson BI; Kidd M; Pavel M; Svejda B; Modlin IM
    Endocrinol Metab Clin North Am; 2011 Mar; 40(1):111-34, viii. PubMed ID: 21349414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear survivin is a powerful novel prognostic marker in gastroenteropancreatic neuroendocrine tumor disease.
    Grabowski P; Griss S; Arnold CN; Hörsch D; Göke R; Arnold R; Heine B; Stein H; Zeitz M; Scherübl H
    Neuroendocrinology; 2005; 81(1):1-9. PubMed ID: 15809513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers and molecular imaging in gastroenteropancreatic neuroendocrine tumors.
    Lindholm DP; Oberg K
    Horm Metab Res; 2011 Nov; 43(12):832-7. PubMed ID: 22009449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors.
    Singh S; Law C
    Expert Rev Gastroenterol Hepatol; 2012 Jun; 6(3):313-34. PubMed ID: 22646254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy.
    Alexandraki KI; Kaltsas G
    Endocrine; 2012 Feb; 41(1):40-52. PubMed ID: 22124940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastroenteropancreatic neuroendocrine neoplasms: current development, challenges, and clinical perspectives.
    Zhang XB; Fan YB; Jing R; Getu MA; Chen WY; Zhang W; Dong HX; Dakal TC; Hayat A; Cai HJ; Ashrafizadeh M; Abd El-Aty AM; Hacimuftuoglu A; Liu P; Li TF; Sethi G; Ahn KS; Ertas YN; Chen MJ; Ji JS; Ma L; Gong P
    Mil Med Res; 2024 Jun; 11(1):35. PubMed ID: 38835066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The somatostatin receptor family--a window against new diagnosis and therapy of cancer].
    Hofsli E
    Tidsskr Nor Laegeforen; 2002 Feb; 122(5):487-91. PubMed ID: 11961977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours.
    Janson ET; Sørbye H; Welin S; Federspiel B; Grønbaek H; Hellman P; Mathisen O; Mortensen J; Sundin A; Thiis-Evensen E; Välimäki MJ; Oberg K; Knigge U
    Acta Oncol; 2010 Aug; 49(6):740-56. PubMed ID: 20553100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Neuroendocrine tumours of pancreas and gastrointestinal tract].
    Tsimmerman IaS
    Klin Med (Mosk); 2009; 87(12):7-13. PubMed ID: 20135878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs).
    Zanini S; Renzi S; Giovinazzo F; Bermano G
    Front Endocrinol (Lausanne); 2020; 11():562505. PubMed ID: 33304317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) 2014.
    Garcia-Carbonero R; JImenez-Fonseca P; Teulé A; Barriuso J; Sevilla I;
    Clin Transl Oncol; 2014 Dec; 16(12):1025-34. PubMed ID: 25183048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastroenteropancreatic Neuroendocrine Tumors.
    Cives M; Strosberg JR
    CA Cancer J Clin; 2018 Nov; 68(6):471-487. PubMed ID: 30295930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How should incidental NEN of the pancreas and gastrointestinal tract be followed?
    Ariotti R; Partelli S; Muffatti F; Andreasi V; Della Sala F; Falconi M
    Rev Endocr Metab Disord; 2018 Jun; 19(2):139-144. PubMed ID: 29527619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution.
    Massironi S; Rossi RE; Casazza G; Conte D; Ciafardini C; Galeazzi M; Peracchi M
    Neuroendocrinology; 2014; 100(2-3):240-9. PubMed ID: 25428270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New perspectives in diagnosis and therapy of endocrine gastroenteropancreatic (GEP) tumors with somatostatin analogues].
    Rubello D; Rufini V; De Carlo E; Martini C; Calcagni ML; Sicolo N; Troncone L; Casara D
    Minerva Endocrinol; 2003 Dec; 28(4):259-96. PubMed ID: 14752399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinico-morphological analysis of the neuroendocrine neoplasms of the gastroenteropancreatic system.
    Delektorskaya VV; Kozlov NA; Chemeris GY
    Klin Lab Diagn; 2013 Oct; (10):48-50, 10-3. PubMed ID: 24640093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
    Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
    Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. State of the art and future prospects in the management of neuroendocrine tumors.
    Oberg K
    Q J Nucl Med; 2000 Mar; 44(1):3-12. PubMed ID: 10932597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.